Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie has demonstrated robust growth potential with management guiding for 2025 global sales in the Neuroscience segment to reach approximately $10.7 billion, reflecting an increase attributable to various key products including Vyalev and Botox Therapeutic. The company's revised fiscal year 2025 earnings per share guidance has been raised to a range of $12.09 to $12.29, alongside a revenue forecast increase to roughly $59.7 billion, indicating strong underlying business performance. Notably, AbbVie reported first-quarter sales of $13.34 billion, surpassing expectations and showcasing the strong commercial success of their immunology and oncology franchises, underscoring their capacity for sustained growth moving forward.

Bears say

The analysis highlights several fundamental reasons for a negative outlook on AbbVie’s stock. Firstly, significant concerns exist regarding the company’s dependence on key products like Humira, which faces increasing biosimilar competition, coupled with disappointing market penetration of Rinvoq and Skyrizi, jeopardizing long-term revenue expectations in key therapeutic areas. Additionally, the Aesthetics segment is adversely impacted by macroeconomic challenges, further compounded by competitive pressures and potential setbacks in AbbVie’s drug pipeline, which could undermine the overall financial stability and growth prospects of the company.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $251.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $251.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.